College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Division of Gastroenterology, National Taiwan University Hospital Bei-Hu Branch, Taipei 108, Taiwan.
Int J Mol Sci. 2020 Aug 20;21(17):5999. doi: 10.3390/ijms21175999.
Even though advancement in medicine has contributed to the control of many diseases to date, cancer therapy continues to pose several challenges. Hepatocellular carcinoma (HCC) etiology is multifactorial. Recently, non-alcoholic fatty liver disease (NAFLD) has been considered as an important risk factor of HCC. NAFLD can be divided into non-alcoholic simple fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) based on histopathological features. Recently, studies have indicated that the gut microbiota is associated with NAFLD and HCC. Therefore, in this review, we have discussed the effects of gut microbiota-related mechanisms, including dysbiosis and gut barrier function, and gut microbiota-derived metabolites on NAFLD and HCC pathogenesis and the potential therapeutic strategies for NAFLD and HCC. With a better understanding of the gut microbiota composition and function, new and improved diagnostic, prognostic, and therapeutic strategies for common liver diseases can be developed.
尽管医学的进步有助于控制迄今为止的许多疾病，但癌症治疗仍然存在一些挑战。肝细胞癌（HCC）的病因是多因素的。最近，非酒精性脂肪性肝病（NAFLD）被认为是 HCC 的一个重要危险因素。根据组织病理学特征，NAFLD 可分为非酒精性单纯性脂肪肝（NAFL）和非酒精性脂肪性肝炎（NASH）。最近的研究表明，肠道微生物群与 NAFLD 和 HCC 有关。因此，在本综述中，我们讨论了与肠道微生物群相关的机制，包括肠道微生物失调和肠道屏障功能以及肠道微生物衍生代谢物对 NAFLD 和 HCC 发病机制的影响，以及 NAFLD 和 HCC 的潜在治疗策略。通过更好地了解肠道微生物群的组成和功能，可以开发出针对常见肝病的新的和改进的诊断、预后和治疗策略。
